title: Paclitaxel/Platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer.
abstract: OBJECTIVE
  The objectives of the present study were to assess the efficacy and tolerability of perioperative paclitaxel/platinum-based chemotherapy and surgery in patients with stage IIIA clinical N2 (cN2) non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Clinical N2 was defined as either >15 mm or >10 mm and multiple nodes on computed tomography (CT) scan. Thirty-four chemotherapy-naive patients with stage IIIA cN2 received preoperative paclitaxel/cisplatin for two cycles and then underwent surgery. The treatment with paclitaxel/carboplatin was repeated for three cycles after the operation.
  
  
  RESULTS
  Of the 34 patients, none achieved a complete response (CR) and 22 achieved a partial response (PR), resulting in a response rate of 65%. Among 29 patients (85%) who had received thoracotomy, 25 (74%) underwent complete resection. Two pathological CRs were observed and mediastinal nodes were free of tumor in 21%. Grade 3-4 toxicity was uncommon and treatment-related mortality was not observed. The median time to progression (TTP) was 12.1 months [95% confidence interval (CI) 8.3-15.9 months] and median overall survival (OS) was 23.6 months (95% CI 17.7-30.2 months).
  
  
  CONCLUSIONS
  Paclitaxel/platinum-based perioperative chemotherapy and surgery for patients with stage IIIA cN2 NSCLC is effective and well tolerated.
authors.affiliation: Department of Internal Medicine, Seoul National University College of Medicine, Chongno-gu, Seoul 110-744, Korea. kimty@snu.ac.kr.
authors.forename: In Sil
authors.initials: IS
authors.lastname: Choi
authors.forename: Do-Youn
authors.initials: DY
authors.lastname: Oh
authors.forename: Jung Hye
authors.initials: JH
authors.lastname: Kwon
authors.forename: Sang-Il
authors.initials: SI
authors.lastname: Kim
authors.forename: Sook Ryun
authors.initials: SR
authors.lastname: Park
authors.forename: Ji-Youn
authors.initials: JY
authors.lastname: Bak
authors.forename: Jee Hyun
authors.initials: JH
authors.lastname: Kim
authors.forename: Dong-Wan
authors.initials: DW
authors.lastname: Kim
authors.forename: Young Tae
authors.initials: YT
authors.lastname: Kim
authors.forename: Tae-You
authors.initials: TY
authors.lastname: Kim
authors.forename: Chul-Kyu
authors.initials: CK
authors.lastname: You
authors.forename: Young Whan
authors.initials: YW
authors.lastname: Kim
authors.forename: Dae Seog
authors.initials: DS
authors.lastname: Heo
authors.forename: Yung-Jue
authors.initials: YJ
authors.lastname: Bang
authors.forename: Sook Whan
authors.initials: SW
authors.lastname: Sung
authors.forename: Chan-Il
authors.initials: CI
authors.lastname: Park
authors.forename: Noe Kyeong
authors.initials: NK
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D019990:Perioperative Care; D010984:Platinum / Q000008:administration & dosage; D011013:Pneumonectomy; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D010984:Platinum; D017239:Paclitaxel